The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus

Current Diabetes Reports

Volumn 13, Issue 3, 2013, Pages 329-341

  Yau, Hanford ^a   Rivera, Kathya ^a   Lomonaco, Romina ^a   Cusi, Kenneth ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Dyslipidemia; Insulin resistance; Nonalcoholic fatty liver disease; Nonalcoholic steatoh epatitis; Peroxisomal proliferator activated receptor ; Pioglitazone; Polycystic ovarian syndrome; Rosiglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ALEGLITAZAR; ALPHA TOCOPHEROL; BALAGLITAZONE; CARBOXY TERMINAL TELOPEPTIDE; CLOMIFENE; CLOMIFENE CITRATE; ESTROGEN; FATTY ACID; FLUTAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PROGESTERONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANOVULATION; ANTIDIABETIC ACTIVITY; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BLADDER CANCER; BONE DENSITY; BONE METABOLISM; BREAST CANCER; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FATTY LIVER; FRACTURE; FRAGILITY FRACTURE; GENDER BIAS; GLUCOSE TOLERANCE; HEART INFARCTION; HEART PROTECTION; HIP FRACTURE; HIRSUTISM; HUMAN; HYPOGLYCEMIA; INFERTILITY; INSULIN RESISTANCE; KIDNEY CANCER; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SIDE EFFECT; WEIGHT GAIN; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG DEVELOPMENT; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; THIAZOLIDINEDIONES;

EID: 84877764669     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0378-8     Document Type: Article

References (111)

1. Cusi K, DeFronzo R. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6:89-131. (Pubitemid 28554676)
2. From the Food and Drug Adminsitration. JAMA. 2000;283:2228.
3. FDA significantly restricts access to the diabetes drug Avandia. In: U.S. Food and Drug Administration; 2010.
4. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710-9. (Pubitemid 32888853)
5. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New Engl J Med. 2006;355:2297-307. (Pubitemid 44837778)
6. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-76. (Pubitemid 38970772)
7. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem. 2008;77:289-312.
8. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572-81. (Pubitemid 44903861)
9. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-73. (Pubitemid 351482795)
10. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:1637-45. (Pubitemid 36623381)
11. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230-5. (Pubitemid 38224230)
12. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab. 2006;8:110-5.
13. Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab. 2010;95:2163-71.
14. Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf. 2004;27:841-56. (Pubitemid 39331683)
15. Hohberg C, Pfutzner A, Forst T, et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab. 2009;11:464-71.
16. Okamoto T, Okamoto L, Lisanti MP, Akishita M. Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes. Geriatr Gerontol Int. 2008;8:218-26.
17. Buchanan TA. (How) Can we prevent type 2 diabetes? Diabetes. 2007;56:1502-7. (Pubitemid 46842593)
18. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic b-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517-22. (Pubitemid 43343284)
19. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. New Engl J Med. 2011;364:1104-15. Very important RCT on the role of pioglitazone to prevent the development of T2DM in subjects with prediabetes.
20. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-104. (Pubitemid 39419498)
21. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPARg agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323-32. (Pubitemid 40629052)
22. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab. 2007;9:640-7. (Pubitemid 47261845)
23. Al Majali K, Cooper MB, Staels B, et al. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia. 2006;49:527-37. (Pubitemid 43277876)
24. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458-64. (Pubitemid 47547772)
25. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New Engl J Med. 2006;355:2427-43. (Pubitemid 44903747)
26. The DREAM. (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Role of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-105. (Pubitemid 44402668)
27. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. (Pubitemid 41416583)
28. Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hyperts. 2005;18:949-57. (Pubitemid 41040266)
29. Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab. 2003;88:3993-6. (Pubitemid 37034557)
30. Sambanis C, Tziomalos K, Kountana E, et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol. 2008;45:23-30. (Pubitemid 351238273)
31. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Phys. 1997;273:F1013-1022.
32. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004;89:1140-5. (Pubitemid 38368402)
33. Zanchi A, Maillard M, Jornayvaz FR, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia. 2010;53:1568-75.
34. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861-6. (Pubitemid 41161118)
35. Balas B, Belfort R, Harrison S, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol. 2007;47:565-70. (Pubitemid 47331745)
36. Berria R, Gastaldelli A, Lucidi S, et al. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006;80:105-12. (Pubitemid 44164408)
37. Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 2007;82:275-81. (Pubitemid 47260544)
38. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-8. (Pubitemid 47403104)
39. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115-28.
40. Dahabreh IJ, Economopoulos K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials. 2008;5:116-20. (Pubitemid 351682521)
41. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-95. (Pubitemid 47403105)
42. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med. 2007;356:2457-71. (Pubitemid 46919772)
43. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-63. (Pubitemid 38196741)
44. Dream Trial Investigators, Dagenais GR, Gerstein HC, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007-14.
45. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-36. (Pubitemid 47464583)
46. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-90. (Pubitemid 40216485)
47. Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007;154:144-50. (Pubitemid 46920490)
48. Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care. 2007;30:384-8. (Pubitemid 46198353)
49. Dormandy J, Bhattacharya M. van Troostenburg de Bruyn AR, et al.: Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32:187-202. A comprehensive in-depth analysis about the efficacy and safety of a TZD in the largest RCT ever perfromed in patients with T2DM and CVD.
50. Hirano M, Nakamura T, Kitta Y, et al. Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. Atherosclerosis. 2009;203:483-8.
51. Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:393-9.
52. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. JACC. 2007;49:1772-80. (Pubitemid 46629127)
53. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129-37.
54. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-51.
55. Spanheimer R. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HOI) tablets for type 2 diabetes mellitus. In: 2007.
56. Colhoun HM, Livingstone SJ, Looker HC, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012;55:2929-37.
57. Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:592-600.
58. Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 2010;95:4560-5.
59. Bazelier MT, Gallagher AM, van Staa TP, et al. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiol Drug Saf. 2012;21:507-14.
60. Hsiao FY, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. Diabetologia. 2010;53:489-96.
61. Bazelier MT, Vestergaard P, Gallagher AM, et al. Risk of fracture with thiazolidinediones: disease or drugs? Calcif Tissue Int. 2012;90:450-7.
62. Aubert R, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12:716-21.
63. Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem. 2012;287:23517-26.
64. Seth A, Sy V, Pareek A, et al. Thiazolidinediones (TZDs) affect osteoblast viability and biomarkers independently of the TZD effects on aromatase. Horm Metab Res. 2013;45:1-8.
65. Lazarenko O, Rzonca S, Hogue W, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669-80. (Pubitemid 46984815)
66. Ali A, Weinstein R, Stewart S, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146:1226-35. (Pubitemid 40289310)
67. Liu L, Aronson J, Huang S, et al. Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int. 2012;91:139-48.
68. Beck Jr GR, Khazai NB, Bouloux GF, et al. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Trans Res. 2013;161:145-55. This study provides a basic and clinical translational explanation on how TZDs may cause bone loss during treament of patients with T2DM.
69. Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95:134-42.
70. Oei L, Zillikens MC, Dehghan A et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: The Rotterdam Study. Diabetes Care. 2013 (epub ahead of print).
71. Plissonnier ML, Fauconnet S, Bittard H, Lascombe I. The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PloS One. 2011;e28354.
72. Li MY, Kong AW, Yuan H, et al. Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice. Curr Cancer Drug Targets. 2012;12:597-606.
73. Lee MW, Kim DS, Kim HR, et al. Cell death is induced by ciglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, independently of PPARgamma in human glioma cells. Biochem Biophys Res Commun. 2012;417:552-7.
74. Yang X, So WY, Ma RC, et al. Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry. Diabetes Res Clin Pract. 2012;97:e13-17.
75. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2012;38:475-84.
76. Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012;118:5403-13.
77. Lai SW, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107:46-52.
78. Walter B, Schrettenbrunner I, Vogelhuber M, et al. Pioglitazone, etoricoxib, interferon-alpha, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med Oncol. 2012;29:799-805.
79. Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462-72.
80. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22:2640-5.
81. He X, Esteva FJ, Ensor J, et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23:1771-80.
82. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953-62.
83. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916-22.
84. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Nat Cancer Inst. 2012;104:1411-21.
85. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54:2009-15.
86. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278-80.
87. Fujimoto K, Hamamoto Y, Honjo S et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012 (epub ahead of print).
88. Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. Diabetes Metab. 2012;36:371-8.
89. Tseng CH. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Form Med Assoc. 2012;111:123-31.
90. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87:2013-7. (Pubitemid 34521483)
91. Nestler J. Metformin for the treatment of the polycystic ovary syndrome. New Engl J Med. 2008;358:47-54.
92. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New Engl J Med. 2007;356:551-66. (Pubitemid 46220816)
93. Li XJ, Yu YX, Liu CQ, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol. 2011;74:332-9.
94. Du Q, Wang YJ, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin. 2012;28:723-30.
95. Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009;94:469-76.
96. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011;95:203-9.
97. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecol Endocrinol. 2010;26:869-73.
98. Vinaixa M, Rodriguez MA, Samino S et al. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PloS one. 2011;e29052.
99. Practice Committee of the American Society for Reproductive Medicine. Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril. 2008;90:S69-73.
100. Bulletins - Gynecology ACoP. ACOG Practice Bulletin No. 108. Polycystic ovary syndrome. Obstet Gynecol. 2009;114:936-49.
101. Roy KK, Baruah J, Sharma A, et al. A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate. Arch Gynecol Obstet. 2010;281:939-44.
102. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-25. Comprehensive review on the role of obesity and dysfunctional adipose tissue in the development of nonalcoholic steatohepatitis (NASH), associated comorbidities such as insulin resistance, T2DM, and CVD and an overview of current treatments.
103. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837-58. Excellent review on the pathogenesis, clinical profile and diagnostic and treatment approaches for nonalcoholic fatty liver disease (NAFLD).
104. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:1389-97. In this study, the authors highlight the relative importance of dysfunctional fat, over BMI per se, in the development of metabolic and histological abnormalities in patients with NAFLD.
105. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med. 2010;362:1675-85. The largest RCT in patients with NASH that highlights the clinical efficacy of vitamin E or pioglitazone in patients without diabetes with this condition.
106. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology. 2010;52:2206-15. A comprehensive review of clinical trials in patients with NASH.
107. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176-84.
108. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-10. (Pubitemid 351916703)
109. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010;51:445-53.
110. Henriksen K, Byrjalsen I, Qvist P, et al. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev. 2011;27:392-401.
111. Herz M, Gaspari F, Perico N, et al. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol. 2011;151:136-42.